Rithm Capital (NYSE:RITM) just crossed $100 billion in investable assets and posted a blowout quarter, yet the stock sits ...
FDA approval sets new context for Protagonist Therapeutics The recent U.S. FDA approval of ICOTYDE for moderate to severe plaque psoriasis puts Protagonist Therapeutics (PTGX) in a new phase.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results